SignalCorporate
Schrödinger outlines 2026 ACV of $222M-$232M while raising drug discovery revenue to $75M-$85M
Schrödinger targets 2026 ACV of $222M-$232M and drug discovery revenue of $75M-$85M.
Context
What happened: Schrödinger outlined 2026 ACV of $222M-$232M and raised its drug discovery revenue target to $75M-$85M during its Q3 2026 earnings call.
Key numbers: 2026 ACV guidance $222M-$232M; drug discovery revenue raised to $75M-$85M; ACV grew 17%, or 24% excluding contribution.
Why it matters: Management said Q3 results reflect sustained commercial momentum and strong progress toward the long-range goals outlined earlier this year.
What changed
Schrödinger outlined 2026 ACV of $222M-$232M and raised its drug discovery revenue target to $75M-$85M during its Q3 2026 earnings call.
Why it matters
Management said Q3 results reflect sustained commercial momentum and strong progress toward the long-range goals outlined earlier this year.